RxDoctor Payments Data

Benjamin Kolner, PA

Physician Assistant · Davenport, IANPI 1871934851

Payments from drug & device makers

$1,090in general payments, 2019–2025

Across 69 payments — averaging $15.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$393
  • AstraZeneca$315
  • Biohaven Pharmaceuticals, Inc.$135
  • Biohaven Pharmaceutical Holding Company Ltd.$67
  • Jazz Pharmaceuticals Inc.$67
  • Novo Nordisk$49
  • plus $65 from 3 others

What the payments were for

  • Food & beverage$1,090100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,090 in reported general payments places this provider in the 80th percentile of 1,140 physician assistant providers in Iowa.

See all physician assistant providers in Iowa

Medicare billing

Part B allowed, 2024
$47,134
Medicare patients
88
Services billed
711

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide57$77,894
FarxigaDapagliflozin Propanediol39$48,998
OzempicSemaglutide26$43,746
EliquisApixaban26$30,538
TrulicityDulaglutide22$28,161
Breztri AerosphereBudesonide/Glycopyr/Formoterol30$28,136
RybelsusSemaglutide21$27,866
Trelegy ElliptaFluticasone/Umeclidin/Vilanter32$25,340
WegovySemaglutide18$23,796
Breo ElliptaFluticasone/Vilanterol44$21,011
Xultophy 100-3.6Insulin Degludec/Liraglutide21$19,329
Tresiba Flextouch U-100Insulin Degludec21$18,413
VraylarCariprazine Hcl13$17,887
Tresiba Flextouch U-200Insulin Degludec16$8,917
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen233$5,061

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Wegovy, Xultophy 100-3.6$49$114,73886 claims
Lilly USA, LLCMounjaro, Trulicity$27$106,05579 claims
AstraZenecaFarxiga, Breztri Aerosphere$315$77,13569 claims
AbbVieVraylar$393$17,88713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,140 physician assistant providers in Iowa.

Other physician assistant in Davenport

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →